10/15/2026
Press releases
Marengo Therapeutics Receives Second U.S. FDA Fast Track Designation for InvikafuspAlfa, Expanding to a Tissue-Agnostic Indication Across Tumor Mutational Burden-HighSolid Tumors That Progress After Prior Therapy, Including Checkpoint Inhibition